Human evidence record · Maridebart cafraglutide

Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — Phase 2

Obesity cohort mean change ranged -12.3% to -16.2% vs -2.5%; obesity+T2D -8.4% to -12.3% vs -1.7%.

Quick read

Human evidence record

What this study tells us

Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.

Who was studied?

Adults with obesity, with and without type 2 diabetes

How many?

n=592

What happened?

Obesity cohort mean change ranged -12.3% to -16.2% vs -2.5%; obesity+T2D -8.4% to -12.3% vs -1.7%.

What stops us overclaiming?

Phase 2; many regimens; unusual molecular modality and long interval; Phase 3 outcomes pending.

Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →

Key result

Obesity cohort mean change ranged -12.3% to -16.2% vs -2.5%; obesity+T2D -8.4% to -12.3% vs -1.7%.

Study details

Study designRandomized, double-blind, placebo-controlled dose-ranging trial

PhasePhase 2

PopulationAdults with obesity, with and without type 2 diabetes

Sample size592

RouteSubcutaneous

Regimen / exposure140, 280 or 420 mg every 4 weeks; 420 mg every 8 weeks; escalation variants

Duration52 weeks

ComparatorPlacebo

Primary endpoint / questionPercent body-weight change

Safety resultGI adverse events common; lower starting dose/escalation improved tolerability; no unexpected signal in publication.

Key limitationsPhase 2; many regimens; unusual molecular modality and long interval; Phase 3 outcomes pending.

Registry / identifierNCT05669599

Evidence verified2026-09-18

Open Maridebart cafraglutide page →Open primary source →